INVO Bioscience, Inc. (INVO) - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 22, 2023, reports the entry into a Material Definitive Agreement by INVO Bioscience, Inc. (the "Company"). The filing details a proposed merger with NAYA Biosciences, Inc. ("NAYA"), a Delaware corporation. The transaction was announced via a joint press release on October 23, 2023.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or margin data for the Company or NAYA. Key financial terms of the proposed transaction include:
- Exchange Ratio: Each outstanding share of NAYA Class A common stock will convert into the right to receive 7.33333 shares of a newly designated INVO Class B common stock (subject to adjustment).
- Share Issuance: Approximately 18,150,000 shares of INVO Class B common stock will be issued to NAYA shareholders.
- Voting Rights: The new INVO Class B common stock will be entitled to ten (10) votes per share.
- Termination Fees: A fee of $1,000,000 is payable by either party if they fail to consummate the merger after satisfying their respective closing conditions.
- Liability Cap: A closing condition requires the aggregate liabilities of the Company (excluding specified liabilities) not to exceed $5,000,000.
Material Changes and Conditions to Closing
The completion of the Merger is subject to several material conditions, including:
- Approval by stockholders of both INVO and NAYA.
- Completion of an interim private offering of INVO common stock generating at least $5,000,000 in gross proceeds.
- Completion of a private offering of INVO common stock at a target price of $5.00 per share to fund one year of operations for the combined company.
- Receipt of waivers from warrant holders regarding fundamental transaction rights.
- Effectiveness of a registration statement on Form S-4.
- Continued listing of INVO stock on NASDAQ and approval for listing of the new shares.
The Merger Agreement includes an "End Date" of December 31, 2023, after which the transaction may be terminated if not consummated.
Guidance, Outlook, and Risks
Management Commentary and Leadership: Upon closing, Dr. Daniel Teper, NAYA's current Chairman and CEO, will become the Chairman and CEO of the combined company. The new board will consist of at least seven directors, with six identified by NAYA (four of whom must be independent) and one being INVO's current CEO, Steven Shum.
Risks and Contingencies: The filing highlights significant risks, including the failure to obtain stockholder or regulatory approvals, the inability to raise the required capital through private offerings, and the potential for the transaction to be terminated. Forward-looking statements regarding the transaction's benefits and timing are subject to uncertainties, including integration challenges, potential litigation, and market conditions.
Investor Verification Checklist
- Verify the status of the required interim private offering ($5M+ gross proceeds) and the $5.00/share private offering.
- Confirm the aggregate liabilities of INVO remain below the $5,000,000 threshold.
- Monitor the filing and effectiveness of the Form S-4 registration statement and proxy materials.
- Check for any waivers obtained from existing INVO warrant holders.
- Review the definitive proxy statement/prospectus for detailed financial projections and risk factors not fully disclosed in this 8-K.